Tian-Li Wang
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (30)
Year:
2026
Proportion of methylated CpG sites in ovarian and mucinous carcinomas. The proportion of methylated CpG sites (mean Beta-values >0.3) are shown for patients with mucinous stomach, mucinous pancreatic, and ovarian mucinous and ovarian endometrioid carcinomas. Methylation was only available for one individual with colorectal mucinous carcinoma (not shown).
Year:
2025
Circos plots of ovarian endometrioid carcinoma samples. Circos plots depict copy number alterations (black line segments interior of the chromosomes) as well as intra- and inter-chromosomal rearrangements (blue lines that connect different portions of the cancer genome).
Year:
2025
Mutation signature analyses. (a) Mutation signatures for ovarian and uterine endometrioid carcinomas visualized with unsupervised clustering. (b) Mutation signatures for ovarian and GI mucinous carcinomas. The intensity of the heatmap colors indicates the percentage of the overall mutational profile for a sample that is explained by the mutation signature.
Year:
2025
Relationship between tumor purity and number of somatic mutations. (a) Tumor purity for multiple histological tumor types were estimated using FACETS. Samples that FACETS did not process due to undetectable copy number changes are marked with an x. (b) Patients with uterine endometrioid adenocarcinomas were more than twice as likely to have a hypermutator defect compared to patients with other cancers, including patients with ovarian endometrioid cancer (95% CI: 1.1 - 4.2-fold increase).
Year:
2025
Integrated genomic analyses of ovarian and colorectal mucinous cancers. Integrated analyses of somatic point mutations, structural variants, including linked amplicons, deletions, and rearrangements, organized by pathways. The top of the figure shows the number of each type of alteration, the middle portion reflects the alterations present in each sample for each gene and pathway, and the bottom shows the mutation spectra.
Year:
2025
WGS analyses of linked amplicons and rearrangements. A, Circos plots for linked amplicons for individual tumor samples with >100 structural variants. Circos plots depict copy number alterations as well as intra- and inter-chromosomal rearrangements. Segmented normalized estimates of read depth were used to identify candidate focal amplifications (teal) and focal deletions (red). Rearranged read pairs and split reads were used to identify inter- and intra-chromosomal rearrangements (blue). B, For linked amplicon graphs, nodes represent genes, node size represents the number of times the segment is represented in the genome, color indicates the chromosome location of the amplified segment, and edges denote segments that are connected in the rearranged cancer genome. Known driver genes indicated by triangles are often hubs in these networks, suggesting that amplification of these genes occurs early and can be connected to many of the other amplicons. C, Reads aligned to the fusion junction of two representative rearrangements. Split reads that span the fusion junction are shown in black, whereas read pairs that reside on either side of the junction are shown in green and blue, providing additional evidence for specific rearrangements.
Year:
2025
Integrated genomic analyses of ovarian and uterine endometrioid adenocarcinomas. Integrated analyses of somatic point mutations, structural variants, including linked amplicons, deletions, and rearrangements, organized by pathways. The top of the figure shows the number of each type of alteration, the middle portion reflects the alterations present in each sample for each gene and pathway, and the bottom shows the mutation spectra.
Year:
2025
Mutations in ESR1 at Tyr537 and Leu536. ESR1 mutations identified in two patients with uterine endometrioid carcinomas occurred at Tyr537, a hotspot most commonly associated with aromatase inhibitor resistance in patients with breast cancer patients, and Leu536. This hotspot is in close proximity to the region of the estrogen receptor that is important for ligand-dependent transcriptional function. The Tyr537 mutations cause a conformational change that constitutively activates the receptor independent of estrogen receptor binding. The Tyr537 residue is highlighted in blue in a three-dimensional view of the ESR1 protein (bottom). Due to its physical proximity to the Tyr537 hotspot, the Leu536 mutation is likely to have the same activating effect on the estrogen receptor.
Year:
2025
Heatmap of methylation values in mucinous and endometrial histotypes. (a) Methylation levels (Betas) at 945 CpG sites having the highest variance across 164 TCGA patient samples that included 77 colorectal mucinous tumors, 37 stomach mucinous tumors, and 46 uterine endometrial samples from normal tissue. (b) Methylation levels at the same CpG sites were obtained from 16 patients with ovarian mucinous carcinomas, 8 patients with ovarian endometrioid carcinomas, 5 patients with stomach mucinous carcinomas, 6 patients with pancreatic mucinous carcinomas, and 1 patient with colorectal mucinous carcinoma.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Collaborators (35)
Samuel Klempner
Associate Professor
Massachusetts General Hospital
Mark A. Atkinson
University of Florida
Ernst Lengyel
University of Chicago
Christopher Douville
Assistant Professor
Johns Hopkins University School of Medicine
Philipp Oberdoerffer
Johns Hopkins University School of Medicine
Martin Taylor
Assistant Professor
Brown University
David Christiani
Harvard University
Nita Ahuja
Chair of Surgery
Yale University
Birgit Schilling
Professor
Buck Institute for Research on Aging
John LaCava
Professor
University of Nebraska Medical Center
Victor E. Velculescu
Assistant/Associate/Professor of Oncology and Pathology
Johns Hopkins University School of Medicine
Kathleen Burns
Professor and Department Chair
Dana-Farber Cancer Institute
David Walt
Harvard University
Michael P. Rout
Rockefeller University
Joseph Franses
Assistant Professor of Medicine
University of Chicago Medicine
Matthew Strickland
Harvard University
Pei-Hsun Wu
Johns Hopkins University
Brian Chait
Rockefeller University
Connie Wu
Assistant Professor
University of Michigan
Peng Huang
Professor
Johns Hopkins University
ravindra uppaluri
Professor
Dana-Farber Cancer Institute
Ie-Ming Shih
Professor
Johns Hopkins University
Sudipto Ganguly
Assistant Professor
Johns Hopkins University
Tomas Mustelin
Professor
University of Washington
David Ting
Associate Professor of Medicine
-
Ronny Drapkin
Franklin Payne Professor of Pathology in Obstetrics and Gynecology
University of Pennsylvania
Barbara S. Slusher
Johns Hopkins University School of Medicine
Hariharan Easwaran
Assistant Professor
Johns Hopkins University School of Medicine
Wen-Chih Cheng
Senior Scientist
Dana-Farber Cancer Institute
Denis Wirtz
TH Professor
Johns Hopkins University
Andre Pinto
University of Miami Miller School of Medicine
Jennifer Fairman
Professor
Johns Hopkins University
Robert B Scharpf
Associate Professor
Johns Hopkins University School of Medicine
Matthew Meyerson
Director, Center for Cancer Genomics
Dana-Farber Cancer Institute
Stephanie Gaillard
Johns Hopkins University
Make your next move.
Prepare your application
Review drafts before you send them.